Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical GLP-1 receptor agonists for healing diabetic foot ulcers
ChiCTR2500096850Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Feb 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4 trial of liraglutide and loxenatide in diabetic foot ulcer (DFU) and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Tongji Hospital. Primary endpoint: Wound area. Started Feb 2025; status: recruiting.
02
Drugs
liraglutideloxenatide
03
Conditions
diabetic foot ulcer (DFU)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500096850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096850.